Literature DB >> 9761128

Cytoplasmic accumulation of alpha-catenin is associated with aggressive features in laryngeal squamous-cell carcinoma.

P Hirvikoski1, E J Kumpulainen, J A Virtaniemi, H J Helin, I Rantala, R T Johansson, M Juhola, V M Kosma.   

Abstract

Aberrations in the function of alpha-catenin (alpha-cat), the anchoring protein of E-cadherin, are believed to cause dysfunction of the cadherin-catenin complex, leading to disturbed cell-cell adhesion. It has been suggested that expression of alpha-cat in human tumours might be a better indicator of aggressive phenotype than expression of E-cadherin. The value of alpha-cat as a prognostic marker in laryngeal squamous cell carcinoma (LSCC) is unclear. To determine the potential prognostic significance of alpha-cat, paraffin-embedded samples from 159 patients with invasive carcinoma left in the section and with long-term follow-up were evaluated immuno-histochemically for alpha-cat expression, and the results were related to histopathological grade, tumour stage and survival. Two patterns of staining were observed: pure membranous staining (57%) and membranous staining with cytoplasmic involvement (43%). Cytoplasmic involvement of alpha-cat was associated with dedifferentiation, advanced tumour stage and nodal status. In addition, supra-glottic tumours showed more often cytoplasmic involvement of alpha-cat than glottic tumours. Patients with cytoplasmic involvement appeared to have a trend towards poor overall survival, though without statistical significance. These results suggest that cytoplasmic involvement of alpha-cat is associated with aggressive behaviour and metastatic phenotype of LSCC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9761128     DOI: 10.1002/(sici)1097-0215(19981023)79:5<546::aid-ijc18>3.0.co;2-#

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Nuclear beta catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma.

Authors:  M J Pukkila; J A Virtaniemi; E J Kumpulainen; R T Pirinen; R T Johansson; H J Valtonen; M T Juhola; V M Kosma
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

2.  Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer.

Authors:  R T Pirinen; P Hirvikoski; R T Johansson; S Hollmén; V M Kosma
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

3.  DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity.

Authors:  Veenu Tripathi; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Mol Cell Biol       Date:  2012-04-02       Impact factor: 4.272

4.  Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues.

Authors:  V Tziortzioti; K H Ruebel; T Kuroki; L Jin; B W Scheithauer; R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 5.  Molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  David Hardisson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-05-08       Impact factor: 2.503

Review 6.  Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis.

Authors:  Jacqueline M Benjamin; W James Nelson
Journal:  Semin Cancer Biol       Date:  2007-09-04       Impact factor: 15.707

7.  Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma.

Authors:  Yeong-Shiau Pu; Chao-Yuan Huang; Yi-Zih Kuo; Wang-Yi Kang; Guang-Yaw Liu; A-Mei Huang; Hong-Jeng Yu; Ming-Kuen Lai; Shu-Pin Huang; Wen-Jeng Wu; Shean-Jaw Chiou; Tzyh-Chyuan Hour
Journal:  J Biomed Sci       Date:  2009-09-12       Impact factor: 8.410

8.  Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma.

Authors:  J P Kallio; P Hirvikoski; H Helin; P Kellokumpu-Lehtinen; T Luukkaala; T L J Tammela; P M Martikainen
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.